Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
The innate immune response to infection or injury involves an antigen-antibody triggered classical pathway (CP) of complement activation, in which soluble and cell surface plasma proteins cooperatively effect elimination of foreign organisms and damaged host cells. However, protracted or dysfunctional complement activation can lead to inflammatory diseases. Complement component 2 bound to C4b is cleaved by classical (C1s) or lectin (MASP2) proteases to produce C4bC2a, a very short-lived C3 convertase (t(1/2) 2 min) that in turn cleaves C3 to C3a and C3b, leading ultimately to formation of Membrane Attack Complex (MAC) and lysis of bacteria and damaged cells. C2 has the same serine protease domain as C4bC2a but in an inactive zymogen-like conformation, requiring cofactor-induced conformational change for activity. Here, we show that C2 has catalytic protease activity in its own right above pH 7, in the absence of cofactor, processing C3 and C3-derived chromogenic peptide fragments. In contrast to the instability of C3 convertase (t(1/2) 2 min, pH 7), the C2 enzyme is indefinitely stable under alkaline conditions, facilitating studies of its catalytic properties and development of small molecule inhibitors. We characterize the catalytic activity of C2 against C3 and short paranitroanilide peptide substrates, and identify potent small molecule inhibitors of C2 that also inhibit classical pathway C3 convertase, MAC formation, and hemolysis of sensitized sheep erythrocytes. These results provide a new avenue and valuable new insights to inhibiting CP complement activation relevant to inflammatory diseases.
Halili
Maria A
MA
Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Qld 4072, Australia.
Ruiz-Gómez
Gloria
G
Le
Giang T
GT
Abbenante
Giovanni
G
Fairlie
David P
DP
D000818:Animals; D003167:Complement Activation; D003175:Complement C2 / Q000737:chemistry / Q000494:pharmacology*; D050679:Complement C2b / Q000378:metabolism; D003176:Complement C3 / Q000378:metabolism; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003179:Complement C3b / Q000378:metabolism; D015935:Complement C4b / Q000378:metabolism; D015938:Complement Membrane Attack Complex; D003171:Complement Pathway, Classical; D004912:Erythrocytes; D006801:Humans; D006863:Hydrogen-Ion Concentration; D011487:Protein Conformation; D017510:Protein Folding; D012697:Serine Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D012756:Sheep
D003175:Complement C2; D050679:Complement C2b; D003176:Complement C3; D015938:Complement Membrane Attack Complex; D003179:Complement C3b; D015935:Complement C4b; D050577:Complement C3-C5 Convertases; D012697:Serine Endopeptidases